Search

Genmab A-S

Uždarymo kaina

2,010 6.41

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1872

Max

1918.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

21M

52M

Pardavimai

-169M

896M

P/E

Sektoriaus vid.

21.639

68.51

Pelnas, tenkantis vienai akcijai

8.48

Pelno marža

5.818

Darbuotojai

3,088

EBITDA

-30M

215M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-1.49% downside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

8.5B

113B

Ankstesnė atidarymo kaina

2003.59

Ankstesnė uždarymo kaina

2010

Genmab A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-06 23:56; UTC

MSCI Inc. shares are higher in after-market trading, gaining since Thursday's close despite earlier pulling back from a session high.

2026-08-06 23:56; UTC

Intercontinental Exchange Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

2026-08-06 23:56; UTC

General Motors Co. shares remain roughly flat in after-market trading. The stock is near the upper end of its one-month range.

2026-08-06 23:56; UTC

KeyCorp shares are modestly higher in after-market trading following Thursday's close, with no specific company news identified to explain the price action.

2026-08-06 23:56; UTC

BWX Technologies shares are higher in after-market hours, following an early spike after the market closed. The stock remains below its 20-day moving average.

2026-08-06 23:56; UTC

Correlated Moves

Lattice Semiconductor is higher in after-market trading, likely influenced by positive momentum in the semiconductor sector and a significant rise in Microchip Technology's stock.

2026-08-06 23:56; UTC

Dycom Industries Inc. is trading higher in after-market hours, reflecting a slight gain since Thursday's close, with no specific news identified.

2026-08-06 23:56; UTC

News

Clear Secure Inc launched a Corporate Memberships program to improve business travel, combining services like CLEAR+ and TSA PreCheck. Shares are trading higher after the announcement.

2026-08-06 23:56; UTC

Tripadvisor Inc shares are higher in after-market trading, reflecting positive sentiment despite broader market challenges. The stock previously peaked before a slight pullback.

2026-08-06 23:56; UTC

Insmed Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

2026-08-06 23:56; UTC

Correlated Moves

Entergy Corp shares advanced in after-market trading, reflecting a positive trend in the electric utilities sector amid broader market dynamics.

2026-08-06 23:56; UTC

NRG Energy Inc shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

2026-08-06 23:56; UTC

News

Shares declined after-hours despite JP Morgan raising price target to $545.

2026-08-06 23:56; UTC

iShares iBoxx $ High Yield Corporate Bond ETF traded roughly flat after market hours, with mixed performance in global equity indices and a stronger U.S. Dollar.

2026-08-06 23:56; UTC

Akebia Therapeutics Inc. shares are higher in after-market trading, advancing modestly since Thursday's close amid routine fluctuations within a narrow range.

2026-08-06 23:56; UTC

Parker-Hannifin Corp shares are higher in after-market hours, recovering from an earlier dip and reflecting a modest uptick since Thursday's close.

2026-08-06 23:56; UTC

Magnite Inc. shares are trading lower in after-market hours, with no specific news identified. The stock remains above its 20-day moving average.

2026-08-06 23:52; UTC

News

First Solar supports Section 232 action on polysilicon imports, benefiting U.S. manufacturing. Shares have moved sharply higher in after-market trading.

2026-08-06 23:51; UTC

Mosaic Co shares traded roughly flat in after-market hours amid a strengthening U.S. Dollar and rising crude oil prices contributing to market volatility.

2026-08-06 23:51; UTC

Correlated Moves

Patrick Industries Inc shares are higher in after-market trading, reflecting positive sector sentiment and following gains in SiteOne Landscape Supply Inc.

2026-08-06 23:51; UTC

VF Corp shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

2026-08-06 23:51; UTC

Exlservice Holdings Inc shares are higher in after-market trading, continuing a recent upward trend and remaining well above their 20-day moving average.

2026-08-06 23:51; UTC

News

The Invesco Currencyshares Japanese Yen Trust is lower in after-market hours, reflecting broader market movements amid ongoing U.S. and Japan currency interventions.

2026-08-06 23:51; UTC

Ralph Lauren Corp shares are trading lower in after-market hours. The stock saw notable volatility today amid broader market factors, including a stronger U.S. Dollar.

2026-08-06 23:51; UTC

Payoneer Global Inc shares are declining in after-market trading, reversing from earlier gains and remaining below the 20-day moving average.

2026-08-06 23:51; UTC

Conagra Brands Inc shares are higher in after-market hours, reaching a session high and remaining above the 20-day moving average. No specific news was identified.

2026-08-06 23:51; UTC

Alliant Energy Corp shares advanced during after-market hours, reflecting unusual strength despite being below the 20-day moving average and recent declines.

2026-08-06 23:51; UTC

UiPath Inc shares are lower in after-market hours following Thursday's close, despite earlier fluctuations. Broader market dynamics may be influencing the decline.

2026-08-06 23:51; UTC

Greenbrier Companies Inc. shares are lower in after-market trading, continuing a trend of declines over three consecutive sessions amid broader market volatility.

2026-08-06 23:51; UTC

News

LeMaitre Vascular Inc shares declined in after-market trading, nearing the lower end of their one-month range amid broader market volatility from Middle East supply concerns.

Genmab A-S Prognozė

Kainos tikslas

By TipRanks

-1.49% į apačią

12 mėnesių prognozė

Vidutinis 2,493.35 DKK  -1.49%

Aukščiausias 3,320 DKK

Žemiausias 308.417 DKK

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Genmab A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

3

Pirkti

2

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat